Company ProfilePremium

Insumos Agroquimicos S.A.

Company Profile Analysis

Ticker: INAG.BA

ESOMAR 23 Corporate BadgeISO Certifications Badge
Insumos Agroquimicos S.A. - Company showcase

Year Founded & Workforce

2002

Insumos Agroquimicos S.A. logo

Insumos Agroquimicos S.A. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Insumos Agroquimicos S.A. Overview

InsuAgro is a mid-sized, asset-light Argentine marketer and distributor of crop-protection and crop-nutrition products, founded in 2002 and controlled since April 2021 by Bioceres Crop Solutions Corp. It sells a broad, largely off-patent portfolio — herbicides, insecticides, fungicides, seed treatments, adjuvants, water correctors, growth regulators, plant-nutrition and biostimulation products — exclusively through agricultural retailers, organised into eleven sales zones each led by a senior agronomist. Its addressable crops span soybean, corn, wheat, sunflower, potato, beans, peanut, pastures and tobacco. Revenue reached ARS 41.1 billion in FY2026, but the business has slipped into operating losses for two consecutive years, carries net debt of ARS 25.4 billion against equity of ARS 6.1 billion, and received a going-concern qualification on its FY2025 accounts. Its strategic future is tightly bound to the restructuring of the Bioceres group, whose founding holding company was declared bankrupt in March 2026.


What the company does. InsuAgro sources formulated agrochemicals and nutrition products from manufacturers and toll formulators — historically disclosed principal suppliers include FMC Química, Cheminova (now part of FMC), Borches y Cía and Rainbow Agrosciences (MAV, Fideicomiso Financiero Insuagro VI presentation, 2020) — and markets them under its own brands to Argentine farm-input retailers. Some descriptions of the business refer to "production" as well as distribution (Fintel; TradingView); the balance sheet shows modest property, plant and equipment (ARS 2,291M at FY2026, including land ARS 663M, buildings ARS 1,677M and machinery ARS 1,201M at gross values per S&P), which is consistent with warehousing and possibly light formulation or repackaging rather than active-ingredient synthesis. The company's own characterisation, used in its securitisation marketing materials, is that of a "comercializadora de insumos agropecuarios" (agricultural inputs trading company) with presence in all of Argentina's farming regions (MAV, Insuagro XII presentation).

Company's own description (paraphrased from its trust-programme presentations and website). InsuAgro describes itself as a company created in 2002 that markets agricultural inputs nationwide, whose wide product range gives it access to the soybean, corn, wheat, sunflower, potato, bean, peanut, pasture and tobacco markets; it sells exclusively to retail outlets through eleven sales zones, each overseen by an experienced agronomist acting as zonal supervisor; it highlights a complete product line, very low geographic and customer concentration, a professional sales force that builds customer loyalty, and agility derived from limited investment in fixed assets. Since 2021 it presents itself as part of the Argentine Bioceres group (MAV, Insuagro XII presentation; company website).

Business model and revenue model. Revenue is essentially 100% product sales (no material service, subscription or licensing revenue is disclosed). S&P's segment data splits revenue into Crop Protection (75.8% of FY2026 revenue) and Crop Nutrition (24.2%). The model is a classic "distributor-formulator" spread business: buy generic molecules on supplier credit (often USD-denominated), brand and position them, and sell on seasonal credit terms to retailers, financing the receivables gap through bank debt, negotiable obligations, and — distinctively — public-offering financial trusts that securitise trade receivables (Fideicomisos Financieros "Insuagro" series). InsuAgro acts as trustor (fiduciante), servicer and collection agent for these trusts, retains the participation certificates, and has agreed to replace defaulted receivables (BIOX 20-F FY2021, Note on Insuagro acquisition).

Value-chain position. Downstream of global and Chinese/Indian active-ingredient manufacturers and formulators, upstream of retailers ("agronomías", cooperatives, distributors) who in turn sell to farmers. InsuAgro does not appear to own molecule IP; its value-add lies in registration management (SENASA product registrations), branding, agronomic advice and credit provision.

Customer types. Agricultural input retailers and distributors only (no direct farmer sales are disclosed). Customer concentration is described as very low (MAV presentations); no customer above 10% of revenue is disclosed.

End-markets. Argentine extensive crops (soy, corn, wheat, sunflower), regional/specialty crops (potato, beans, peanut, tobacco) and pastures. Geographic coverage includes the northwest, northeast and central farming regions (Fintel profile) — effectively the whole Argentine grain belt.

Independent characterisation. InsuAgro is a sub-scale generic agrochemical brand-owner whose economics are driven less by product innovation than by working-capital management in a high-inflation, devaluation-prone, credit-intensive market. In FY2022 it earned an 11% EBIT margin; by FY2025–FY2026 the same gross margin structure (22–23%) no longer covered a sharply higher SG&A base (SG&A ≈ 24% of revenue), and financial costs, FX losses and bad-debt provisions (ARS 1,069M in FY2026) pushed it into net losses. Its strategic value inside the Bioceres group was as a distribution channel and as an additional crop-protection catalogue alongside sister company Rizobacter; that rationale is now subordinate to group liquidity.

Strategy

Stated strategy (themes, paraphrased). No investor-day material or strategic plan for InsuAgro is publicly available. Its recurring self-description emphasises: (1) a broad, complete product line; (2) low customer and geographic concentration; (3) a professional agronomist-led sales force that builds retailer loyalty; (4) asset-light agility to adapt to market and macro changes (MAV presentations); and, since 2021, (5) belonging to the Bioceres group, with "the same values" and "more strength and projects" (company website).

Group-level strategic context (Bioceres Crop Solutions). BIOX's stated rationale in 2021 was the reorganisation of its crop-protection business segment (BIOX 20-F FY2021). In FY2025–FY2026, BIOX announced a transition in its seed business model and the elimination of low-margin, working-capital-intensive sales, which reduced Q1 FY2026 revenue 17% to US$77.5M while gross margin rose from 40% to 47% (Safras, reporting BIOX Q1 FY2026). InsuAgro's FY2026 inventory and payables reduction is directionally consistent with this group-wide working-capital discipline — an analyst inference.

Announced initiatives in the last 24 months (InsuAgro-specific):

Medium-term targets / guidance: None publicly disclosed.

Products & Services

InsuAgro publishes a product catalogue on its website (Productos section) and product manuals ("Manuales InsuAgro"), but the individual product pages could not be retrieved in this research. The table below lists every product name verifiable from public sources; technical specifications, launch years and pricing are not publicly disclosed in the sources reviewed. Active-ingredient descriptions marked "(inferred from name)" are analyst inferences from the brand name and should be verified against SENASA registrations.

Crop Protection

ProductCategoryDescription / likely active ingredientTarget customerLaunch / version yearPricing model
AffinityHerbicide (category as listed by aggregators; inferred)—Retailers serving extensive-crop growers——
Danken Max——Retailers——
Dicamba BlockHerbicideDicamba-based broadleaf herbicide (inferred from name); used in fallow and pre-plant weed controlRetailers / extensive crops——
Florane——Retailers——
MetolacloroHerbicideS-metolachlor/metolachlor pre-emergent grass herbicide (inferred from name) for soy, corn, sunflower, peanutRetailers——
Super OnecideHerbicideGraminicide (inferred: "Onecide" is a known fluazifop-p-butyl brand family); post-emergent grass control in broadleaf cropsRetailers——
Imiseed FlowSeed treatmentImidacloprid-based flowable seed treatment (inferred from name)Retailers / seed treaters——
IshioilAdjuvantOil-based adjuvant (inferred from name)Retailers——
Paraquat StocktonHerbicideParaquat desiccant/burndown herbicide (inferred from name)Retailers——
Salix——Retailers——
LamdaInsecticideLambda-cyhalothrin pyrethroid insecticide (inferred from name)Retailers——
Fungicides (range)FungicideProducts not individually named in sources reviewedRetailers——
Growth regulatorPlant growth regulatorNamed in MAV presentations as a category; product not namedRetailers——
Water correctorsSpray-water conditionersNamed as a category in MAV presentationsRetailers——

Crop Nutrition / Biostimulation

Product lineCategoryDescriptionTarget customerLaunch yearPricing
Plant nutrition lineFoliar/soil nutritionListed by S&P business description; product names not disclosedRetailers——
Plant biostimulationBiostimulantsListed by S&P business descriptionRetailers——
Environmental formulationsLower-impact formulationsListed by S&P business description; the website also has a "Medio Ambiente" sectionRetailers——
InoculantsBiologicalsTradingView lists inoculants among productsRetailers——

Services

Agronomic advisory: via zonal agronomist supervisors (eleven zones) — bundled with product sales, not separately priced (MAV presentations).

"Nuevas Tecnologías": a website section indicates new-technology content, likely linked to Bioceres-group technologies; specifics not publicly disclosed.

Commentary. The portfolio is characteristic of a generic "me-too" player: widely available molecules (dicamba, paraquat, metolachlor, imidacloprid, lambda-cyhalothrin, fluazifop) where differentiation rests on formulation quality, availability, credit and service. Paraquat's regulatory status is a latent portfolio risk (banned in many jurisdictions; Argentine regulatory status should be monitored).

Financial Narrative

Source for all figures unless noted: S&P Global Market Intelligence via StockAnalysis.com (income statement, balance sheet, cash-flow statement pages; last updated 14 Sep 2026). ARS millions; nominal as originally reported per fiscal year; fiscal years end 30 June.

Income statement

Dividends per share: S&P records ARS 7.195 per share attributable to FY2024 only. Conflict: TradingView states INAG has never paid dividends, while the S&P cash-flow series shows common dividends paid in FY2022–FY2025 (see 6.4). The discrepancy may reflect distributions to non-controlling holders of consolidated trusts being classified as dividends by the aggregator, or simply an aggregator error; it could not be resolved from primary filings.

TTM check: for the twelve months to 31 March 2026, StockAnalysis showed revenue of ARS 43,820M (+0.3%) and net income of ARS −1,850M (snapshot of 22 Jul 2026).

Margins (%)

SG&A-to-revenue is analyst-computed; others from S&P: Revenue CAGR FY2022–FY2026: 46.4% per year nominal (analyst-computed: (41,059 / 8,940)^(1/4) − 1).

Commentary — income statement. Three inflections stand out. (1) FY2022 was the high-water mark for profitability: 27% gross margin and 11% EBIT margin, the year that triggered the US$0.965/share earn-out to sellers under Bioceres' acquisition agreement (BIOX 20-F FY2025). (2) FY2024's nominal explosion (+244%) coincided with the December 2023 peso devaluation; it inflated revenue but also produced ARS 4,403M of FX losses, offset by ARS 2,145M of interest/investment income and ARS 2,237M of other non-operating gains, leaving a near-zero pre-tax result. (3) FY2025–FY2026 structural deterioration: gross margin held at 22–23%, but SG&A rose to ~24% of revenue (the FY2025 SG&A jump of 60% nominal against revenue growth of 29% indicates either cost inflation running ahead of pricing, higher freight/logistics, or — likely significant — bad-debt provisions, which rose from ARS 317M in FY2024 to ARS 520M in FY2025 and ARS 1,069M in FY2026 per the cash-flow add-backs). Operating income turned negative and financial charges (interest, FX, other) produced pre-tax losses of ARS 3.5bn and 2.5bn. FY2026 also benefited from ARS 791M of "other unusual items" (nature not disclosed), without which the pre-tax loss would have been ~ARS 3.3bn.

Balance sheet

Goodwill is zero at the InsuAgro level (goodwill from the 2021 acquisition sits in Bioceres' consolidated accounts). Lease totals are analyst-summed from current and long-term lease lines.

Source conflict: FinancialFilings.com reports FY2025 total assets of ARS 60,933.35M and total equity of ARS 7,049.64M per the annual report filed 9 Sep 2025, versus S&P's ARS 60,921M and ARS 7,050M — immaterial differences, likely rounding/classification.

Commentary — balance sheet. The balance sheet is dominated by trade receivables (64% of total assets in FY2026) funded by supplier credit and debt. Two FY2026 movements are striking: accounts payable fell by ARS 15.0bn (from 37.6bn to 22.5bn) while long-term debt rose by ARS 16.8bn (from 6.2bn to 23.0bn) and short-term debt fell by ARS 4.8bn. The most plausible reading — an analyst inference not confirmed by primary disclosure — is that overdue supplier balances and short-term financing were refinanced or converted into long-dated financial debt (possibly with related parties or principal suppliers), which explains both the jump in working capital to ARS 23.9bn and the improvement in the current ratio. Equity has been eroded by ARS 1.2bn across FY2025–FY2026 in nominal terms (a much larger real erosion), and leverage (debt/equity) has risen to 4.5x.

Cash flow

Capex is shown blank for FY2022 because S&P reports no figure; FY2026 dividends shown as 0 because none were reported; buybacks: none disclosed in any year.

Source conflict: FinancialFilings.com cites FY2025 cash from operations of ARS −1,159.15M per the annual report, versus ARS −656.97M in the S&P series. The difference (~ARS 502M) likely reflects classification of interest or securitisation flows; the primary figure should be preferred once retrieved.

Commentary — cash flow. For four consecutive years (FY2022–FY2025) InsuAgro consumed operating cash to fund working-capital growth, financed by net debt issuance of ARS 13.8bn cumulatively. FY2026 is the first year of positive operating cash flow (ARS 4.9bn), driven primarily by an inventory release of ARS 3.9bn rather than by profitability; the cash was used to repay ARS 4.1bn of net debt. Capex is negligible (under 0.2% of revenue), confirming the asset-light model. Cash interest paid tripled in FY2026 to ARS 1.3bn even as the income-statement interest expense fell, suggesting settlement of accrued interest during refinancing.

Ratios (analyst-computed from year-end balances unless noted)

ROIC = EBIT × (1 − 35%) / (equity + total debt − cash & short-term investments); 35% is Argentina's top statutory corporate rate used as a notional assumption. Working-capital day counts use year-end balances against annual flows; because June year-end balances are restated to closing-date currency while flows accumulate through the year, day counts are upward-biased in high-inflation years and should be read directionally only.

Commentary — ratios. Returns collapsed from an exceptional FY2022 (ROE 36%, ROIC ~39%) to negative territory. Interest coverage has been at or below 1x since FY2023, meaning the business has not covered its financing cost from operations for three years. The FY2026 cash-conversion cycle lengthened to ~183 days because payables days fell sharply (supplier balances moved to financial debt), a shift that transfers liquidity pressure from suppliers to lenders. The improvement in the current ratio to 1.85x is a product of term-out rather than of organic de-leveraging.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsRepresentative products (where identifiable)

Crop Protection

Herbicides, insecticides, fungicides, seed treatments ("curasemillas"), adjuvants/synergists, water correctors, growth regulators

Affinity, Danken Max, Dicamba Block, Florane, Metolacloro, Super Onecide, Imiseed Flow, Ishioil, Paraquat Stockton, Salix, Lamda (Fintel)

Crop Nutrition

Plant-nutrition line, plant biostimulation, environmental formulations

Product names not publicly disclosed in sources reviewed

Crop Protection

31,1370

Crop Nutrition

9,9230

Revenue by Segment

SegmentFY2023FY2024FY2025FY2026

Crop Protection revenue (ARS Mn)

7,88326,20234,62031,137

Crop Nutrition revenue (ARS Mn)

1,8847,3988,6889,923

Total revenue (ARS Mn)

9,76733,60143,30941,059

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%)

SegmentFY2024FY2025FY2026

Crop Protection YoY growth (%)

232.432.1-10.1

Crop Nutrition YoY growth (%)

292.717.414.2

Total YoY growth (%)

244.028.9-5.2

Revenue by Segment (%)

SegmentFY2023FY2024FY2025FY2026

Crop Protection share of revenue (%)

80.778.079.975.8

Crop Nutrition share of revenue (%)

19.322.020.124.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (ARS Mn)

8,9409,76733,60143,30941,059

Revenue growth YoY (%)

100.819.24244.0328.89-5.19

Cost of revenue (ARS Mn)

6,4957,57825,34433,77831,476

Gross profit (ARS Mn)

2,4462,1898,2579,5319,584

SG&A (ARS Mn)

1,4821,5076,1609,8859,901

Operating income / EBIT (ARS Mn)

987.48681.052,073-340.2-336.63

D&A used in EBITDA (ARS Mn)

34.4639.5147.66232.34238.7

EBITDA (ARS Mn)

1,022720.552,220-107.86-97.93

Interest expense (ARS Mn)

747.18716.151,9821,7051,269

Interest and investment income (ARS Mn)

419.57717.582,145533.79323.39

Currency exchange gain or loss (ARS Mn)

-128.52-311.52-4,403-1,120-783.93

Other non-operating income or expense (ARS Mn)

32.69-49.162,237-757.61-1,244

Pre-tax income (ARS Mn)

565.73283.58-22.91-3,525-2,485

Income tax expense (ARS Mn)

248.99296.51-253.24-1,279-183.51

Net income (ARS Mn)

316.74-12.93230.33-2,246-2,301

EPS basic (ARS)

14.40-0.5910.47-102.07-104.60

EPS diluted (ARS)

14.40-0.5910.47-102.07-104.60

Weighted shares basic (M)

2222222222

Advertising expense (ARS Mn)

—72.52480.56332.98265.43

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

27.3622.4124.5722.0123.34

SG&A to revenue (%)

16.5815.4318.3322.8224.11

Operating margin (%)

11.046.976.17-0.79-0.82

EBITDA margin (%)

11.437.386.61-0.25-0.24

Pre-tax margin (%)

6.332.90-0.07-8.14-6.05

Net margin (%)

3.54-0.130.69-5.18-5.60

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (ARS Mn)

5,28812,49753,74860,92157,212

Cash and equivalents (ARS Mn)

28.4325.55158.441,2441,908

Short-term investments (ARS Mn)

418.33650.831,12817.1620.17

Cash and short-term investments (ARS Mn)

446.77676.391,2861,2611,928

Trade accounts receivable (ARS Mn)

2,6636,68334,89239,61636,738

Total receivables (ARS Mn)

2,7877,26536,90141,32839,131

Inventory (ARS Mn)

1,7423,90012,24113,67910,114

Total current assets (ARS Mn)

5,00211,87850,42956,76652,076

Net PP&E (ARS Mn)

228.89452.671,5201,8892,291

Intangible assets (ARS Mn)

35.1574.47375.28599.75669.17

Goodwill (ARS Mn)

00000

Accounts payable (ARS Mn)

2,9126,11530,61537,57822,531

Short-term debt (ARS Mn)

841.732,8517,4919,0324,220

Long-term debt (ARS Mn)

379.55778.376,7336,19522,995

Lease liabilities total (ARS Mn)

04.231.33118.1878.77

Total debt incl. leases (ARS Mn)

1,2213,63414,25515,34627,294

Net debt (ARS Mn)

774.512,95712,96814,08525,366

Total current liabilities (ARS Mn)

3,9139,44039,52347,61528,148

Total liabilities (ARS Mn)

4,40910,53746,51153,87151,152

Shareholders' equity (ARS Mn)

879.61,9597,2377,0506,060

Working capital (ARS Mn)

1,0892,43810,9059,15123,929

Book value per share (ARS)

39.9889.06328.94320.44275.44

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (ARS Mn)

-1,228-2,780-4,860-656.974,866

Capital expenditures (ARS Mn)

—24.256.66.822.45

Purchase of intangibles (ARS Mn)

8.449.46140.54174.1952.83

Free cash flow (ARS Mn)

-1,228-2,805-4,916-663.764,843

Free cash flow margin (%)

-13.73-28.72-14.63-1.5311.80

Change in working capital (ARS Mn)

-2,417-3,494-7,561-1,4653,266

Provision and write-off of bad debts (ARS Mn)

44.0828.59316.64519.91,069

Net debt issued or repaid (ARS Mn)

1,1333,0857,8931,681-4,084

Common dividends paid (ARS Mn)

41.93106.01100.62158.30

Share buybacks (ARS Mn)

00000

Cash interest paid (ARS Mn)

—334.25688.62416.041,302

Investing cash flow (ARS Mn)

147.81-456.15-3,507517.92886.35

Financing cash flow (ARS Mn)

1,0913,2348,5001,224-5,088

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on year-end equity (%)

36.0-0.73.2-31.9-38.0

ROA on year-end assets (%)

6.0-0.10.4-3.7-4.0

ROIC after 35% notional tax (%)

38.89.06.7-1.0-0.7

Current ratio (x)

1.281.261.281.191.85

Debt to equity (x)

1.391.861.972.184.50

Net debt to EBITDA (x; blank where EBITDA negative)

0.764.105.84——

EBIT interest coverage (x)

1.320.951.05-0.20-0.27

Asset turnover on year-end assets (x)

1.690.780.630.710.72

Days sales outstanding (days)

108.7249.7379.0333.9326.6

Days inventory outstanding (days)

97.9187.8176.3147.8117.3

Days payables outstanding (days)

163.6294.5440.9406.1261.3

Cash conversion cycle (days)

43.0143.0114.475.6182.6

Revenue by Region

RegionFY2023FY2024FY2025FY2026

Argentina revenue (ARS Mn)

9,76733,60143,30941,059

Rest of world revenue (ARS Mn)

0000

Region Margins & Growth (%)

RegionFY2024FY2025FY2026

Argentina revenue growth (%)

244.028.9-5.2

Share Price History

DatePrice (ARS)NoteSource

12 Sep 2025

7,400

Reported +146.7% move

Fintel

22 Jan 2026

7,000

1-year CAGR shown as 152%

iocharts

24 Apr 2026

~5,886 implied

From market cap ARS 129,500M / 22M shares

Fintel (analyst-derived)

7 Jul 2026

700

Likely erroneous or anomalous print

StockAnalysis

22 Jul 2026

7,000

52-week range shown 650–7,000

StockAnalysis

1 Sep 2026

6,850

Last verified trade

StockAnalysis

Valuation Multiples

MultipleAt ARS 6,850 (mkt cap ~ARS 150,700M)At ~ARS 700 (mkt cap ~ARS 15,400M per StockAnalysis)

P/E

n/m (loss)

n/m (loss)

EV/EBITDA

n/m (negative EBITDA)

n/m

EV/Sales

~4.29x (EV ~ARS 176,100M)

~0.99x (EV ~ARS 40,800M)

P/B

~24.9x

~2.5x

P/FCF

~31x

~3.2x (StockAnalysis shows 3.11x)

Dividends & Capital Returns and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Dividends paid in cash (ARS Mn)

41.93106.01100.62158.30

Dividend per share recorded (ARS)

——7.195——

Capital Instruments

InstrumentAgencyRatingDate

Corporate issuer rating (Moody's/S&P/Fitch)

—

Not rated

—

FF Insuagro VI Class A debt securities

FIX SCR (Fitch affiliate)

AAsf(arg)

2020

FF Insuagro VI Class B

FIX SCR

Asf(arg)

2020

FF Insuagro VI participation certificates

FIX SCR

CCCsf(arg)

2020

FF Insuagro VII Class A

FIX SCR

AAsf(arg)

Dec 2020

FF Insuagro VII Class B

FIX SCR

Asf(arg)

Dec 2020

FF Insuagro VII participation certificates

FIX SCR

CCsf(arg)

Dec 2020

Later trusts (VIII–XII)

FIX SCR

—

2021–2025

Debt Maturity Profile

Maturity bucketFY2022FY2023FY2024FY2025FY2026

Short-term debt within 12 months (ARS Mn)

841.732,8517,4919,0324,220

Long-term debt beyond 12 months (ARS Mn)

379.55778.376,7336,19522,995

Lease liabilities (ARS Mn)

04.231.33118.1878.77

Analyst Conclusions

Management guidance: None publicly disclosed.

Consensus growth expectations: None (no coverage).

Bull case

  1. Cash inflection is real: FY2026 operating cash flow of ARS 4.9bn and net debt repayment of ARS 4.1bn show the business can self-fund when it shrinks inventory; with debt termed out (84% long-term), management has runway to restore margins.

  2. Margin repair is a cost problem, not a gross-margin problem: gross margin (23.3%) is intact; returning SG&A from ~24% to the ~16–18% of FY2022–FY2024 would restore a mid-single-digit EBIT margin, and normalising bad-debt charges toward FY2024 levels alone would add ~ARS 0.75bn.

  3. Strategic optionality: a distressed parent may sell its 61.3% stake; a better-capitalised acquirer could value InsuAgro's retailer network and registrations, and minority holders would be entitled to a mandatory tender offer under Argentine rules.

Bear case

  1. Persistent losses and going-concern doubt: two consecutive years of EBIT losses, sub-1x interest coverage since FY2023, and an auditor going-concern flag suggest equity (ARS 6.1bn, falling) may continue to erode.

  2. Contagion from the Bioceres collapse: bankruptcy of Bioceres S.A., BIOX's going-concern doubt, Nasdaq deficiency and New York litigation could restrict supplier credit, trust-market access and bank lines for InsuAgro, or force asset sales on unfavourable terms.

  3. Commoditised portfolio under deflation: Crop Protection revenue is shrinking (−10.1% nominal FY2026, far worse in real terms) amid generic price pressure, while receivables equal ~6x equity, leaving little buffer if the farm credit cycle turns.

Key catalysts and monitorables (next 12 months)

  • Q1 FY2027 results (quarter to 30 Sep 2026; expected ~November 2026): gross margin, SG&A ratio, bad-debt charges.

  • Whether the auditor's FY2026 report retains the going-concern emphasis.

  • Disclosure of terms behind the FY2026 long-term debt increase (lender, currency, covenants, related-party status).

  • BIOX restructuring outcomes: Nasdaq listing status, New York litigation, any disposal of the InsuAgro stake, and the Bioceres S.A. bankruptcy proceedings in Rosario.

  • New financial-trust issuance under the INSUAGRO programme (a signal of market access).

  • 2026/27 Argentine planting season (soybean vs corn area) and weather.

  • Argentine FX regime and inflation path, which drive FX losses and nominal working capital.

  • Regulatory actions on paraquat, glyphosate, dicamba.

Analyst verdict. Insumos Agroquímicos is a small, asset-light Argentine generic agrochemical marketer whose economics have deteriorated sharply since its peak FY2022 profitability. The core franchise — a broad portfolio sold through a diversified network of retailers, supported by agronomist-led zonal coverage and a long record of receivables securitisation — is still intact at the gross-margin line, which has held at 22–23%. The problem lies below gross profit: SG&A has climbed to roughly a quarter of revenue, credit losses have tripled in two years, and financing and FX costs have consumed whatever operating profit remained. The result is two consecutive years of net losses of about ARS 2.2–2.3 billion, an auditor's going-concern emphasis, and leverage of 4.5x debt-to-equity.

FY2026 brought a genuine but low-quality improvement: positive operating cash flow driven by inventory liquidation and a conversion of short-term supplier and bank obligations into long-term debt. This buys time but does not by itself restore profitability, and the terms of the new long-dated liabilities are undisclosed — a critical gap for any credit or equity view.

The overriding variable is the parent. Bioceres Crop Solutions, which owns 61.3%, carries its own going-concern doubt, faces a Nasdaq deficiency notice and noteholder litigation, and sits beneath a founding holding company that a Rosario court declared bankrupt in March 2026. InsuAgro's access to supplier credit, trust markets and bank lines is likely to track the group's credibility.

For equity investors, INAG is effectively uninvestable on fundamentals alone: it has a ~28% float, sporadic trading, contradictory price prints differing tenfold, and no coverage. Its value lies chiefly in event optionality — a stake sale triggering a tender offer. For credit investors, senior trust tranches backed by diversified receivables remain the safer exposure. Overall stance: high risk, speculative; monitor parent restructuring and FY2026 audit opinion before any position.


Principal sources consulted

  • S&P Global Market Intelligence data via StockAnalysis.com — INAG income statement, balance sheet, cash flow, KPIs, company profile (data updated 14 Sep 2026; prices through 1 Sep 2026).

  • Bioceres Crop Solutions Corp., Form 20-F for FY2021, FY2022, FY2023, FY2025 (SEC EDGAR); BIOX 4Q25 consolidated financial statements.

  • Mercado Argentino de Valores — Fideicomiso Financiero Insuagro VI, VII, VIII, IX, XII prospectuses, subscription notices and presentations; Bolsa de Comercio de Rosario — Insuagro X prospectus supplement (Dec 2022).

  • InsuAgro corporate website (insuagro.com.ar), retrieved Oct 2026.

  • MarketScreener/Zonebourse (results calendar, going-concern headline, valuation); Fintel; TradingView; Simply Wall St; iocharts; Twelve Data; FinancialFilings.com.

  • Press: iProfesional (Apr 2021; Dec 2025–Jul 2026), El Economista (Mar 2026), Canal 26 (Mar 2026), Bichos de Campo (2025–2026), El Cronista (2025–2026), Forbes Argentina (2026), Safras (BIOX Q1 FY2026), Infocampo, Agrofy News, Mercado, AgroLatam, De Frente al Campo (CASAFE and INTA market data).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitlePrior rolesEducation

Luis S. Delcassé

Chairman, Chief Executive Officer and Managing Director

Not publicly disclosed (Twelve Data also lists him as CEO)

—

Darío Severi

Administration and Finance Manager

——

Ing. Hermann Welz

Sales Manager

—

Agronomist/engineer title indicated

Ing. Rodolfo Vicetto

Marketing and Production Manager

—

Engineer title indicated

Ing. José Mrejen

Commercial Director and Director

—

Engineer title indicated

“—” = not publicly disclosed.

Governance Overview

ItemDetailSource

Board size

Three directors at April 2021 closing (two replaced by Bioceres nominees)

BIOX 20-F FY2022

Committees

Statutory Comisión Fiscalizadora (supervisory committee) exists; audit committee status not publicly disclosed (CNV rules generally require an audit committee for listed companies; but small issuers may qualify for exemptions)

FinancialFilings.com (Comisión Fiscalizadora report)

Chair/CEO separation

Data provider shows combined Chairman/CEO role

StockAnalysis/EODHD

Dual-class structure

Class A shares: 5 votes; Class B (listed): 1 vote

BIOX 20-F FY2025

Major Shareholders

HolderShares% equity% votesSource

Bioceres Crop Solutions Corp. (Nasdaq: BIOX)

13,489,99061.3261.22

BIOX 20-F FY2023

Public free float

~6.2M (est. from 28.2% float)

~28.2

—

MarketScreener

Other holders (residual, likely legacy founders/insiders)

~2.3M (residual, analyst-derived)

~10.5

—

Analyst derivation

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompetitorTypeOverlap with InsuAgroRelative positioning

Rizobacter Argentina S.A. (sister, BIOX)

Domestic formulator; adjuvants, inoculants, biologicals

Adjuvants, seed treatments, nutrition

Larger, industrial capacity, group flagship; overlapping channel

Syngenta (ChemChina/Sinochem)

Multinational R&D

Herbicides, fungicides, seed treatments

Premium brands, broad portfolio

Bayer Crop Science

Multinational R&D

Herbicides, fungicides, insecticides

Premium brands, traits integration

Corteva Agriscience

Multinational R&D

Herbicides, insecticides

Premium brands, seeds

BASF Agricultural Solutions

Multinational R&D

Fungicides, herbicides

Premium fungicides

FMC

Multinational (also a disclosed InsuAgro supplier)

Insecticides, herbicides

Supplier-competitor

UPL / UPL Argentina

Global generic

Broad generic portfolio

Scale generic, aggressive pricing

ADAMA

Global generic

Broad generic portfolio

Scale generic

Nufarm

Global generic

Herbicides

Generic herbicides

Albaugh (incl. Atanor in Argentina)

Global generic with local manufacturing

Herbicides (glyphosate, 2,4-D)

Local production advantage

Red Surcos

Domestic formulator/distributor

Generic portfolio

Direct domestic peer

Gleba

Domestic formulator

Generic portfolio

Direct domestic peer

Chemotécnica

Domestic formulator

Generic portfolio

Direct domestic peer

Agrofina

Domestic formulator

Generic portfolio

Direct domestic peer

Summit Agro (Sumitomo)

Distributor

Specialty/generic

Japanese-backed distributor

Peer Comparison FY2026

MetricInsuAgro (FY2026, ARS)Bioceres Crop Solutions (parent, US$)Rizobacter

Revenue

ARS 41,059M

——

Revenue growth

−5.2% nominal

−17% (Q1 FY2026)

—

Gross margin

23.3%

47% (Q1 FY2026)

—

Operating margin

−0.8%——

Leverage

Net debt ARS 25.4bn; D/E 4.5x

Financial debt US$228.8M (Mar 2026); equity US$64.1M (FY end)

Restructured ~US$42M ONs (May 2026)

Recent Developments

Contract wins, product launches, layoffs/hiring and regulatory actions specific to InsuAgro: not publicly disclosed in the period.

Company Snapshot

2002

Founded

Ciudad Autónoma de Buenos Aires, Argentina

Headquarters

SWOT Analysis

Strengths

  • Broad generic portfolio across major crops — products spanning herbicides, insecticides, fungicides, seed treatments, adjuvants, growth regulators and water correctors for soy, corn, wheat, sunflower, potato, beans, peanut, pastures and tobacco (MAV presentations; Fintel product list).
  • Diversified retailer base — very low customer and geographic concentration, served via eleven zones (MAV Insuagro VI/XII presentations).
  • Asset-light model — capex of only ARS 22.5M in FY2026 (0.05% of revenue) (S&P).
  • Proven securitisation access — at least seven public financial trusts (VI–XII) under a programme of up to US$28M, with senior tranches rated AAsf(arg) by FIX (MAV prospectuses).
  • Gross margin resilience — gross margin has held in a 22–27% band in each of the last five years (S&P).
  • Cash turnaround in FY2026 — operating cash flow of ARS 4,866M after four years of outflows (S&P).
  • Growing Crop Nutrition line — +14.2% nominal in FY2026 while the total business shrank (S&P KPIs).

Weaknesses

  • Operating losses — EBIT of ARS −340M (FY2025) and ARS −337M (FY2026) (S&P).
  • Going-concern qualification on FY2025 accounts (MarketScreener, 9 Sep 2025).
  • High leverage — total debt ARS 27.3bn vs equity ARS 6.1bn (D/E 4.5x) at FY2026 (S&P; analyst-computed).
  • Sub-1x interest coverage since FY2023 (analyst-computed from S&P).
  • Cost base growth — SG&A rose from 16.6% to 24.1% of revenue between FY2022 and FY2026 (S&P).
  • Rising credit losses — bad-debt provisions ARS 317M → 520M → 1,069M (FY2024–FY2026) (S&P cash-flow add-backs).
  • Opaque disclosure — no public employee count, segment profit, auditor name in aggregators, or detailed governance data.

Opportunities

  • Biologicals growth — Argentine bio-inputs market US$118–124M with biocontrol and biofungicides growing fast (CASAFE/Pampas Group–Somera studies).
  • Macroeconomic normalisation — lower inflation would reduce FX and monetary losses (which totalled ARS 784M FX loss in FY2026) and stabilise working capital.
  • Group portfolio synergies — potential to distribute Rizobacter/Bioceres biologicals and adjuvants through InsuAgro's retailer network (strategic logic of the 2021 acquisition; BIOX 20-F FY2021).
  • Debt term-out — long-term debt now 84% of financial debt (ARS 22,995M of 27,294M), providing time for operational repair (S&P).
  • Consolidation of distressed peers — a stressed generic sector may allow share gains for survivors.
  • Potential strategic sale — a parent under pressure (BIOX equity US$64.1M) may monetise its 61.3% stake, possibly to a better-capitalised owner (speculative; no deal reported).

Threats

  • Parent-group distress — Bioceres S.A. bankruptcy (3 Mar 2026); BIOX going-concern doubt and Nasdaq deficiency notice (Forbes Argentina; BIOX 4Q25 statements).
  • Litigation at parent level — New York noteholder suit (Nov 2025) against BIOX and certain subsidiaries (Forbes Argentina); whether InsuAgro is a named defendant is not disclosed.
  • Generic price deflation — Crop Protection revenue fell 10.1% nominal in FY2026 (S&P KPIs).
  • Credit-chain risk — receivables of ARS 36.7bn equal ~6x equity (S&P).
  • Regulatory restrictions on key molecules (paraquat, glyphosate) and municipal application buffers (Agrofy; De Frente al Campo).
  • Climate — drought shocks such as 2022/23 depress demand and collections (industry context).
  • Delisting/illiquidity risk — sporadic trading and contradictory price prints (ARS 700 vs ARS 6,850) (StockAnalysis).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb 2025 (context)BIOX cuts earnings outlook citing difficult Argentine conditions; Rizobacter pays ~US$21.5M ON instalment Bichos de CampoEarly signal of group stress
10 Feb 2025 (context)InsuAgro publishes H1 FY2025 results MarketScreenerRoutine
5 Mar 2025 (context)BIOX shifts seed strategy and signs agreement with GDM El Cronista (headline)Group refocus
Late Jun 2025FIX downgrades Rizobacter's long-term issuer rating; extended after Bioceres S.A. default Bichos de Campo citing FIXGroup credit deterioration; read-across to InsuAgro funding costs
30 Jun 2025InsuAgro FY2025 year-end: net loss ARS 2,246M S&P via StockAnalysisFirst large loss
3 Jul 2025Bioceres S.A. defaults on ~US$5.3M promissory notes FIX via Bichos de CampoContagion risk to group
9 Sep 2025InsuAgro files FY2025 annual report FinancialFilings.com; MarketScreenerRevenue ARS 43,309M; equity ARS 7,050M
9 Sep 2025InsuAgro auditor expresses doubt over going concern MarketScreener/ZonebourseKey governance/solvency flag
Sep 2025BIOX FY2025 audited financial statements include substantial doubt about BIOX's going concern BIOX 4Q25 financial statementsParent-level solvency flag
12 Sep 2025INAG trades at ARS 7,400, reported +146.7% vs prior reference price FintelThin-market repricing
11 Nov 2025InsuAgro Q1 FY2026 results (to 30 Sep 2025) MarketScreenerRoutine
Nov 2025Four secured noteholders sue BIOX and certain subsidiaries in New York for alleged contractual breaches Forbes ArgentinaParent litigation
Q1 FY2026 (reported late 2025)BIOX Q1 FY2026 revenue US$77.5M (−17%), net loss US$7.5M, gross margin 47% SafrasParent restructuring of sales model
16 Dec 2025Bioceres S.A. board resolves to petition for its own bankruptcy; Moolec loses control of Bioceres S.A. iProfesionalGroup control upheaval
Dec 2025Press reports Bioceres group "splashed" by a new agro-sector default El Cronista (headline, 11 Dec 2025)Reputational
20 Jan 2026Bioceres S.A. shareholders ratify bankruptcy petition Bichos de CampoControl dispute escalates
22 Jan 2026INAG data snapshot: price ARS 7,000; 1-year return ~152% iochartsPrice reference
12 Feb 2026InsuAgro H1 FY2026 results (to 31 Dec 2025) MarketScreenerRoutine
Feb 2026Rizobacter renegotiates debt maturities; FIX downgrade follows El CronistaSister-company stress
3 Mar 2026Rosario court declares Bioceres S.A. bankrupt (negative equity ~US$110M); orders scrutiny of group's transnational corporate/financial structure iProfesional; El Economista; Bichos de CampoFounding holding bankrupt; BIOX shares down ~90%, penny stock
Mar 2026BIOX equity reported at US$95.7M (vs US$295.2M Jun 2025); total financial debt US$228.8M Forbes ArgentinaParent balance-sheet erosion
24 Apr 2026Fintel cites INAG market cap ARS 129,500MValuation reference
12 May 2026InsuAgro 9M FY2026 results (to 31 Mar 2026) MarketScreener; StockAnalysisTTM revenue ARS 43.8bn; TTM net loss ARS 1.85bn
29 May 2026Rizobacter secures >86% acceptance on ~US$42M ON exchange (new 9% notes due Sep 2029) El CronistaGroup liquidity breathing room
Jun 2026BIOX files criminal complaint against a former director over an alleged ~US$12M share-transfer fraud (5.3M shares) El Cronista; Forbes ArgentinaGovernance controversy at parent
30 Jun 2026InsuAgro FY2026 year-end: revenue ARS 41,059M; net loss ARS 2,301M; OCF +ARS 4,866M; LT debt ARS 22,995M S&P via StockAnalysisCash turnaround but continued losses
7 Jul 2026Data provider shows INAG close of ARS 700 (−4.1%) — inconsistent with ~ARS 7,000 prints before and after StockAnalysis profileData anomaly / illiquidity flag
Mid-2026BIOX receives Nasdaq minimum-bid-price deficiency notice; equity at fiscal year-end reported at US$64.1M; Pro Farm Group (U.S.) foreclosed Forbes ArgentinaParent listing risk
1 Sep 2026Last verified INAG trade ARS 6,850 StockAnalysisPrice reference
Early Sep 2026InsuAgro FY2026 annual results released (scheduled 4 Sep 2026; aggregator updated 14 Sep 2026) StockAnalysisAnnual report

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue rose from ARS 8,940 Mn in FY2022 to ARS 41,059 Mn in FY2026.
Insumos Agroquimicos S.A. — Income Statement: Revenue & Gross Profit
Series (ARS Mn)FY2022FY2023FY2024FY2025FY2026
Revenue8,9409,76733,60143,30941,059
Cost of revenue6,4957,57825,34433,77831,476
Gross profit2,4462,1898,2579,5319,584

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.